Speeding trial deployments from site identification to activation, while ensuring regulatory compliance
SAN FRANCISCO, September 13, 2016 -- goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today that PSI CRO has chosen goBalto's complete end-to-end platform for starting clinical trials, from site identification, feasibility and selection, through to activation, with comprehensive metrics to track adherence to timelines and budget.
PSI CRO is using goBalto's Select module to assist with site identification, feasibility assessment and selection of sites for a multi-country Phase II Infectious Disease Study, which will then be seamlessly initiated for subject enrollment using goBalto's flagship product, Activate.
Select goes beyond simple aggregation of site data, providing a data driven approach to weighing selection and performance variables to aid in the identification of sites and target populations ideally suited to studies.
Kirill Soldatov, Director of Process Improvement at PSI CRO stated, "Select simplifies the process of finding investigative sites by ensuring optimal fit and its integrated workflows allow our globally dispersed clinical research teams to collaborate in real-time. Investigative sites can then be quickly setup to enroll trial subjects using Activate."
Activate allows PSI CRO to further accelerate study startup, enhance real-time oversight to clinical operations management with at-a-glance critical path study and country level reports, and improve site communications.
"The process of conducting clinical trials is often long, complex, bureaucratic and, above all else, expensive. There has been a strong focus on study conduct and quality, but as stakeholders are increasingly aware that better study startup processes are linked to shorter clinical timelines, the emphasis has been shifting in that direction," said Jae Chung, goBalto's founder and president. "PSI CRO is driving the adoption of this innovation by automating a cumbersome industry process, with the goal of getting medicines to those in need faster."